Ravulizumab Shows Favorable Survival and Improves Clinical Markers in Children With HSCT ‐ TMA : Results of a Phase 3 Trial
Year: 2026
Type: article
Study design: Clinical Trial
Abstract: Hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) is a rare, life-threatening complication that can lead to multiorgan failure and death. The ALXN1210-TMA-314 global, Phase 3, open-label, single-arm trial evaluated ravulizumab, a C5 inhibitor, for treatment of HSCT-TMA in children (NCT04557735). Eligible participants aged ≥ 28 days to < 18 years had HSCT-TMA within 12 months from HSCT, which persisted for ≥ 72 h despite initial management. Participants received weight-based ravulizumab plus best supportive care during the 26-week treatment period, followed by a 26-week follow-up period. The protocol-defined primary endpoint was complete TMA response during the treatment period. Key secondary endpoints included individual TMA response components (proteinuria, platelets, and lactate dehydrogenase/schistocytes), overall survival (OS), and safety. Of 41 enrolled participants (mean age, 7.6 years; 51.2% female), 28 (68.3%) completed treatment, and 24 (58.5%) completed the study. Through the treatment period, 7 (17.1%) participants achieved complete TMA response, and 22 (53.7%) achieved partial TMA response; 29 (70.7%) participants achieved improvement in ≥ 1 TMA response component. Estimated OS was 92.6% at Day 100, 87.2% at Week 26, and 73.4% at Week 52. During treatment, a low incidence of serious TEAEs was assessed by investigators as related to ravulizumab (3 participants, 7.3%); no new safety signals were identified. No meningococcal infections were reported. In this global Phase 3 trial in children with HSCT-TMA, ravulizumab treatment resulted in excellent OS and normalization of early laboratory markers of TMA in many patients. TRIAL REGISTRATION: NCT04557735.
Source: American Journal of Hematology
DOI: 10.1002/ajh.70545
Institutions: Università Cattolica del Sacro Cuore, Bambino Gesù Children's Hospital, Emory University, Children's Healthcare of Atlanta, Hospital Universitario La Paz, Northwestern University, Lurie Children's Hospital, Alexion Pharmaceuticals (United States), Schneider Children's Medical Center, National Health Service, Birmingham Children's Hospital, Nagoya University, Fukushima Medical University Hospital, Kobe Children's Hospital, Seoul National University, Seoul National University Children's Hospital, University of California, San Francisco
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $5,450
Funders: AstraZeneca, Alexion Pharmaceuticals
OpenAlex ID: W7226015226
